Cyclerion Therapeutics, Inc. (CYCN) symbol metrics page

Cyclerion Therapeutics Inc. (CYCN) NASDAQ

$3.05 - (-)

Market Cap: $8.27M

As of 04/22/24 12:00 AM EDT. Market closed.

Cyclerion Therapeutics Inc. (CYCN)
NASDAQ

$3.05
- (-)

Market Cap: $8.27M

As of 04/22/24 12:00 AM EDT. Market closed.

Add to Portfolio

cyclerion therapeutics, inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of various treatments for serious and orphan diseases. its product candidates include olinciguat, an orally administered vascular soluble guanylate cyclase (sgc) stimulator that is in phase ii studies for the treatment of sickle cell disease (scd); praliciguat, ... read more

COMPANY PROFILE

Sector

Professional, Scientific, and Technical Services

Industry

Research and Development in Biotechnology (except Nanobiotechnology)

CEO Compensation (Base)

$100,000

CEO Compensation (Total)

$5.16M

URL

Address

Sector

Professional, Scientific, and Technical Services

Industry

Research and Development in Biotechnology (except Nanobiotechnology)

Full Time Employees

CEO Compensation (Base)

$100,000

CEO Compensation (Total)

$5.16M

URL

Address

PRICE CHART FOR CYCLERION THERAPEUTICS INC

YTD

MAX

From: To:

NEWS

INSIDEARBITRAGE ARTICLES

KEY STATS

Open

Previous Close

$3.05

Days Range

$2.77 - $2.98

52 week range

$1.75 - $6.75

Volume

717

Avg. Volume (30 days)

4,788

Market Cap

$8.27M

Dividend Yield

P/E

(0.77)

Shares Outstanding

2,710,096

Open

Previous Close

$3.05

Days Range

$2.77 - $2.98

52 week range

$1.75 - $6.75

Volume

717

Avg. Volume (30 days)

4,788

Market Cap

$8.27M

Dividend Yield

P/E

(0.77)

Shares Outstanding

2,710,096

FINANCIAL STATEMENTS FOR CYCLERION THERAPEUTICS INC

Open in:

INSIDER TRANSACTIONS FOR CYCLERION THERAPEUTICS INC

Owner	Relationship	Date	Transaction	Cost	# Shares	Value($)	Total Shares	Form 4
MCGUIRE TERRANCE	Director	Aug 09, 2023	Sale	$3.39	8	27	0	Aug 11, 2023, 04:25 PM
Hecht Peter M	Chief Executive Officer	May 19, 2023	Option Exercise	$8.68	225,000	1,953,000	327,385	May 22, 2023, 08:43 PM
MCGUIRE TERRANCE	Director	Jun 03, 2021	Buy	$3.12	3,322	10,365	24,957	Jun 07, 2021, 05:36 PM
MCGUIRE TERRANCE	Director	Jun 03, 2021	Buy	$3.12	92,831	289,633	697,313	Jun 07, 2021, 05:36 PM
Hecht Peter M	Chief Executive Officer	Jun 03, 2021	Buy	$3.28	823,170	2,699,998	2,047,698	Jun 07, 2021, 05:25 PM
Hecht Peter M	Chief Executive Officer	May 06, 2021	Buy	$2.43	302,000	733,860	1,224,528	May 10, 2021, 08:45 AM
Hecht Peter M	Chief Executive Officer	May 05, 2021	Buy	$2.53	398,001	1,006,943	922,528	May 06, 2021, 09:27 PM
Hecht Peter M	Chief Executive Officer	May 04, 2021	Buy	$2.29	300,000	687,000	524,527	May 06, 2021, 09:27 PM
Gjino Anjeza	Chief Financial Officer	Feb 25, 2021	Sale	$4.00	1,824	7,296	31,599	Mar 01, 2021, 04:23 PM
Wright Christopher I	Chief Medical Officer	Feb 25, 2021	Sale	$3.99	2,637	10,522	42,728	Mar 01, 2021, 12:00 AM
Currie Mark G	President and CSO	Dec 28, 2020	Sale	$3.01	20,107	60,522	251,648	Dec 30, 2020, 01:14 PM
Busch Andreas	Chief Innovation Officer	Nov 09, 2020	Buy	$2.53	125,000	316,250	254,704	Nov 12, 2020, 05:05 PM
Huyett William	Chief Financial Officer	Nov 06, 2020	Sale	$2.52	3,827	9,644	67,590	Nov 10, 2020, 07:07 PM
Huyett William	Chief Financial Officer	Feb 21, 2020	Sale	$5.12	3,559	18,222	71,417	Feb 25, 2020, 04:11 PM
Currie Mark G	President	Dec 30, 2019	Sale	$2.48	25,000	62,000	271,755	Dec 31, 2019, 05:55 PM
Currie Mark G	President	Dec 27, 2019	Sale	$2.55	25,000	63,750	296,755	Dec 31, 2019, 05:55 PM
Busch Andreas	Chief Innovation Officer	Nov 15, 2019	Buy	$1.82	125,000	227,500	125,000	Nov 19, 2019, 04:02 PM
Huyett William	Chief Financial Officer	Nov 08, 2019	Sale	$2.05	3,922	8,040	74,976	Nov 12, 2019, 04:26 PM
Hecht Peter M	Chief Executive Officer	Jul 10, 2019	Option Exercise	$6.04	2,000	12,080	225,192	Jul 12, 2019, 04:09 PM
MCGUIRE TERRANCE	Director	Apr 08, 2019	Buy	$16.00	21,635	346,160	21,635	Apr 10, 2019, 04:14 PM
MCGUIRE TERRANCE	Director	Apr 08, 2019	Buy	$16.00	604,482	9,671,712	604,482	Apr 10, 2019, 04:14 PM
SCHULMAN AMY W	Director	Apr 08, 2019	Buy	$16.00	21,635	346,160	21,635	Apr 10, 2019, 04:13 PM
SCHULMAN AMY W	Director	Apr 08, 2019	Buy	$16.00	604,482	9,671,712	604,482	Apr 10, 2019, 04:13 PM
Currie Mark G	President	Apr 02, 2019	Buy	$14.81	270,107	4,000,285	321,755	Apr 03, 2019, 07:42 PM

Load More Insider Transactions

Buy Sale Option Exercise

Owner	Relationship	Date	Value($)
MCGUIRE TERRANCE	Director	08/09/2023	27
Hecht Peter M	Chief Executive Officer	05/19/2023	1,953,000
MCGUIRE TERRANCE	Director	06/03/2021	10,365
MCGUIRE TERRANCE	Director	06/03/2021	289,633
Hecht Peter M	Chief Executive Officer	06/03/2021	2,699,998
Hecht Peter M	Chief Executive Officer	05/06/2021	733,860
Hecht Peter M	Chief Executive Officer	05/05/2021	1,006,943
Hecht Peter M	Chief Executive Officer	05/04/2021	687,000
Gjino Anjeza	Chief Financial Officer	02/25/2021	7,296
Wright Christopher I	Chief Medical Officer	02/25/2021	10,522
Currie Mark G	President and CSO	12/28/2020	60,522
Busch Andreas	Chief Innovation Officer	11/09/2020	316,250
Huyett William	Chief Financial Officer	11/06/2020	9,644
Huyett William	Chief Financial Officer	02/21/2020	18,222
Currie Mark G	President	12/30/2019	62,000
Currie Mark G	President	12/27/2019	63,750
Busch Andreas	Chief Innovation Officer	11/15/2019	227,500
Huyett William	Chief Financial Officer	11/08/2019	8,040
Hecht Peter M	Chief Executive Officer	07/10/2019	12,080
MCGUIRE TERRANCE	Director	04/08/2019	346,160
MCGUIRE TERRANCE	Director	04/08/2019	9,671,712
SCHULMAN AMY W	Director	04/08/2019	346,160
SCHULMAN AMY W	Director	04/08/2019	9,671,712
Currie Mark G	President	04/02/2019	4,000,285

Load More Insider Transactions

FUNDS WITH A POSITION IN CYCLERION THERAPEUTICS INC

Fund	# Shares Owned	% of Portfolio	% Change	Investing Style
GEODE CAPITAL MANAGEMENT, LLC	31,259	0.00001%	1.66%	Other
BLACKROCK INC.	17,169	0%	-4.62%	Other

CHANGE IN SHARES OUTSTANDING FOR CYCLERION THERAPEUTICS INC

STOCK BUYBACKS FOR CYCLERION THERAPEUTICS INC

Period of Report

Previous Period

% Change in Shares

10-K/10-Q Filings

Quarter

12/31/2023

09/30/2023

-11.88%

View

12/31/2023

09/30/2022

12.93%

View

Period of Report: 12/31/2023

10-K/10-Q Filings: View